Enhanced SARS-CoV-2 Antibody Response After a Third Heterologous Vector Vaccine Ad26COVS1 Dose in mRNA Vaccine-Primed Kidney Transplant Recipients.

Transpl Int · 2022 · PMC8980220 · PMID 35391899

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

showed a trendp = 0.058so close (0.05 < p ≤ 0.1)

They showed a trend of lower mean eGFR (48.1 vs . 55.5 ml/min/1.73 m 2 ; p = 0.058) and being treated more often with mycophenolic acid (84% vs . 64%; p = 0.090).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.